Venetoclax in biomarker‐selected multiple myeloma patients: Impact of exposure on clinical efficacy and safety
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Venetoclax in biomarker‐selected multiple myeloma patients: Impact of exposure on clinical efficacy and safety
Authors
Keywords
-
Journal
HEMATOLOGICAL ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2023-09-24
DOI
10.1002/hon.3222
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Venetoclax exposure‐efficacy and exposure‐safety relationships in patients with treatment‐naïve acute myeloid leukemia who are ineligible for intensive chemotherapy
- (2022) Deanna Brackman et al. HEMATOLOGICAL ONCOLOGY
- Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)
- (2021) Nizar J. Bahlis et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma
- (2021) Luciano J Costa et al. Blood Advances
- Review of Venetoclax in CLL, AML and Multiple Myeloma
- (2021) Masa Lasica et al. Journal of Personalized Medicine
- Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure
- (2020) Brian J. Ball et al. Blood Advances
- Exposure–response analysis of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphocytic leukemia: pooled results from a phase 1b study and the phase 3 MURANO study
- (2019) Rong Deng et al. LEUKEMIA & LYMPHOMA
- Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
- (2018) J. Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Exposure-response evaluations of venetoclax efficacy and safety in patients with non-Hodgkin lymphoma
- (2017) Apurvasena Parikh et al. LEUKEMIA & LYMPHOMA
- Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies
- (2016) AW Roberts et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Metabolism and Disposition of a Novel B-Cell Lymphoma-2 Inhibitor Venetoclax in Humans and Characterization of Its Unusual Metabolites
- (2016) Hong Liu et al. DRUG METABOLISM AND DISPOSITION
- Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy
- (2016) Kevin J. Freise et al. HEMATOLOGICAL ONCOLOGY
- Myeloma today: Disease definitions and treatment advances
- (2015) S. Vincent Rajkumar AMERICAN JOURNAL OF HEMATOLOGY
- Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax
- (2015) S M Matulis et al. LEUKEMIA
- The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
- (2013) C Touzeau et al. LEUKEMIA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now